IP Library Granted Patent US 7,345,086
Granted Patent B2
US 7,345,086 · App. 10/838,470 · Granted Mar 18, 2008

Uses of ion channel modulating compounds

Assignee: Cardiome Pharma Corp.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,345,086
App. No.
10/838,470
Granted
Mar 18, 2008
Kind
B2
Abstract

Methods, formulations, dosing regimes, and routes of administration for the treatment or prevention of arrhythmias, including the treatment or prevention of atrial fibrillation. In these methods, the disease or condition is treated or prevented by administering one or more ion channel modulating compounds to a subject, where the ion channel modulating compound or compounds produce specific plasma levels in the subject. The ion channel modulating compounds may be cycloalkylamine ether compounds, particularly cyclohexylamine ether compounds.

Claims (29)

1. A method for producing in the blood plasma of a human subject a total concentration of an ion channel modulating compound having a concentration of greater than about 0.1 μg/ml for at least some time for the treatment of an arrhythmia, the method comprising administering to the subject an amount of an ion channel modulating compound in one or more doses of a formulation, wherein each dose of the formulation independently comprises an ion channel modulating compound of formula

including isolated enantiomeric, diastereomeric and geometric isomers thereof and mixtures thereof, or a solvate or pharmaceutically acceptable salt thereof;

wherein R 4 and R 5 are independently selected from hydroxy and C 1 -C 6 alkoxy.

2. The method of claim 1 , wherein the total concentration of the ion channel modulating compound has a C max of greater than about 0.1 μg/ml.

3. The method of claim 1 or 2 , wherein each dose of the formulation is administered intravenously.

4. The method of claim 3 , wherein the formulation is an isotonic intravenous solution of the ion channel modulating compound.

5. The method of claim 1 or 2 , wherein each dose of the formulation is administered orally.

6. The method of claim 5 , wherein the formulation is a solid or liquid dosage form of the ion channel modulating compound.

7. The method of claim 2 , wherein the total concentration of the ion channel modulating compound in the blood plasma of the subject has a C max of between about 0.3 μg/ml and about 20 μg/ml.

8. The method of claim 2 , wherein the total concentration of the ion channel modulating compound in the blood plasma of the subject has a C max of between about 0.3 μg/ml and about 15 μg/ml.

9. The method of claim 1 , wherein the total concentration of the ion channel modulating compound in the blood plasma of the subject is greater than about 0.1 μg/ml for a period of time of at least about 10 hours.

10. The method of claim 1 , wherein the total concentration of the ion channel modulating compound in the blood plasma of the subject is greater than about 1.0 μg/ml for a period of time of at least about 2 hours.

11. The method of claim 1 or 2 , wherein the ion channel modulating compound is administered in two or more doses.

12. The method of claim 1 , wherein the method comprises administering to the subject one or two doses of the formulation, and wherein each dose of the formulation comprises a monohyrochloride salt of the formula

13. A method for producing in the blood plasma of a human subject a total concentration of an ion channel modulating compound with a mean trough concentration of greater than about 1 ng/ml and/or a steady state concentration of greater than about 1 ng/ml for reducing the recurrence of an arrhythmia in a human that has previously undergone one or more arrhythmias, the method comprising administering to the subject an amount of an ion channel modulating compound in three or more doses of a formulation, wherein each dose of the formulation independently comprises an ion channel modulating compound of formula

including isolated enantiomeric, diastereomeric and geometric isomers thereof and mixtures thereof, or a solvate or pharmaceutically acceptable salt thereof;

wherein R 4 and R 5 are independently selected from hydroxy and C 1 -C 6 alkoxy;

14. The method of claim 13 , wherein the total concentration of the ion channel modulating compound in the blood plasma of the subject has a mean trough concentration of less than about 20 μg/ml and/or a steady state concentration of less than about 20 μg/ml.

15. The method of claim 13 , wherein each dose of the formulation is administered intravenously.

16. The method of claim 15 , wherein the formulation is an isotonic intravenous solution of the ion channel modulating compound.

17. The method of claim 13 , wherein the dose or doses are administered orally.

18. The method of claim 17 , wherein the formulation is a solid or liquid dosage form of the ion channel modulating compound.

19. The method of claim 13 , wherein the total concentration of the ion channel modulating compound in the blood plasma of the subject has a mean trough concentration of less than about 10 μg/ml and/or a steady state concentration of less than about 10 μg/ml.

20. The method of claim 13 , wherein the total concentration of the ion channel modulating compound in the blood plasma of the subject has a mean trough concentration of between about 1 ng/ml and about 10 μg/ml and/or a steady state concentration of between about 1 ng/ml and about 10 μg/ml.

21. The method of claim 20 , wherein the total concentration of the ion channel modulating compound in the blood plasma of the subject has a mean trough concentration of between about 0.3 μg/ml and about 3 μg/ml and/or a steady state concentration of between about 0.3 μg/ml and about 3 μg/ml.

22. The method of claim 13 , wherein the ion channel modulating compound is administered in two or more doses.

23. The method of claim 13 , wherein the method comprises administering to the subject one or two doses of the formulation, and wherein each dose of the formulation comprises a monohyrochloride salt of the formula

24. The method of claim 1 , wherein the method comprises administering to the subject one or two doses of the formulation, and wherein each dose of the formulation comprises a monohydrochloride salt of the formula

25. The method of claim 13 , wherein the method comprises administering to the subject one or two doses of the formulation, and wherein each dose of the formulation comprises a monohydrochloride salt of the formula

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 10, 2018
From: CARDIOME PHARMA CORP.
To: CORREVIO CANADA CORP.
Reel/Frame 046831/0078 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 10, 2018
From: CORREVIO CANADA CORP.
To: CORREVIO INTERNATIONAL SÀRL
Reel/Frame 046831/0227 →
RELEASE OF SECURITY INTEREST Recorded Jun 20, 2016
From: MIDCAP FINANCIAL TRUST
To: CARDIOME PHARMA CORP.; CARDIOME, INC.; ARTESIAN THERAPEUTICS, INC.; MURK ACQUISITION SUB, INC.; CORREVIO LLC; CARDIOME INTERNATIONAL AG; CORREVIO INTERNATIONAL SARL; CORREVIO (UK) LTD.; CARDIOME UK LIMITED; CORREVIO (AUSTRALIA) PTY LTD.
Reel/Frame 038961/0202 →
SECURITY INTEREST Recorded Jul 24, 2014
From: CARDIOME PHARMA CORP.; CARDIOME, INC.; ARTESIAN THERAPEUTICS, INC.; MURK ACQUISITION SUB, INC.; CORREVIO LLC; CARDIOME INTERNATIONAL AG; CORREVIO INTERNATIONAL SARL; CORREVIO (UK) LTD.; CARDIOME UK LIMITED; CORREVIO (AUSTRALIA) PTY LTD.
To: MIDCAP FUNDING V, LLC
Reel/Frame 033407/0314 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 12, 2004
From: BEATCH, GREGORY N.; EZRIN, ALAN M.
To: CARDIOME PHARMA CORP.
Reel/Frame 015238/0784 →
Continuity (11)
Provisional Application 6055940500 · Apr 1, 2004
Provisional Application 6055871600 · Apr 1, 2004
Provisional Application 6054494100 · Feb 13, 2004
Provisional Application 6052825100 · Dec 8, 2003
Provisional Application 6052716900 · Dec 4, 2003
Provisional Application 6052691100 · Dec 3, 2003
Provisional Application 6051648600 · Oct 31, 2003
Provisional Application 6051624800 · Oct 31, 2003
Provisional Application 6049339200 · Aug 7, 2003
Provisional Application 6046715900 · May 2, 2003
Related Publication 20050026993A1 · Feb 3, 2005